Physician profile

Joy Sladek

Family · Branchburg, NJ

NPI 1396354635

$303.78

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$76.04
Education$13.35

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Exeltis, USA INC. $58.82 2022-2023 Nuvessa, Slynd
Bayer Healthcare Pharmaceuticals INC. $49.81 2021-2022
Mayne Pharma Commercial LLC $45.43 2022-2023
Abbvie INC. $43.25 2022
Hologic Sales and Service, LLC $20.03 2022
Pfizer INC. $15.71 2023
Evofem Biosciences, INC. $14.99 2022
Daiichi Sankyo INC. $14.89 2022
Agile Therapeutics, INC. $14.28 2022
Millicent US INC $13.35 2024
Avion Pharmaceuticals $13.22 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Joy Sladek

$303.78

in general payments reported 2019-2025

Years
2021-2024
Top company
Exeltis, USA INC.

https://glasscript.com/doctor/10904895/joy-sladek

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.